Insider Buying: Cosmos Health (NASDAQ:COSM) CEO Acquires $35,111.16 in Stock

Cosmos Health Inc. (NASDAQ:COSM) CEO Grigorios Siokas bought 55,732 shares of Cosmos Health stock in a transaction dated Tuesday, November 25th. The shares were acquired at an average price of $0.63 per share, with a total value of $35,111.16. Following the completion of the purchase, the chief executive officer directly owned 6,383,625 shares in the company, valued at $4,021,683.75. This trade represents a 0.88% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Grigorios Siokas also recently made the following trade(s):

• On Friday, November 21st, Grigorios Siokas purchased 56,080 shares of Cosmos Health stock. The stock was acquired at an average price of $0.68 per share, for a total transaction of $38,134.40.
• On Thursday, November 20th, Grigorios Siokas purchased 51,315 shares of Cosmos Health stock. The shares were acquired at an average cost of $0.62 per share, with a total value of $31,815.30.
• On Wednesday, November 19th, Grigorios Siokas acquired 61,614 shares of Cosmos Health stock. The stock was bought at an average price of $0.65 per share, for a total transaction of $40,049.10.

Cosmos Health Price Performance

Shares of COSM opened at $0.64 on Friday. The company’s 50-day moving average is $0.90 and its 200-day moving average is $0.72. The company has a debt-to-equity ratio of 0.25, a current ratio of 0.99 and a quick ratio of 0.84. The firm has a market capitalization of $22.35 million, a PE ratio of -0.85 and a beta of 5.32. Cosmos Health Inc. has a fifty-two week low of $0.28 and a fifty-two week high of $1.32.

Cosmos Health (NASDAQ:COSM) last announced its quarterly earnings results on Friday, November 14th. The company reported ($0.17) EPS for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.16). The company had revenue of $17.11 million during the quarter, compared to analyst estimates of $16.40 million. Cosmos Health had a negative net margin of 31.01% and a negative return on equity of 33.19%. Equities analysts forecast that Cosmos Health Inc. will post -0.78 EPS for the current year.

Institutional Trading of Cosmos Health

An institutional investor recently raised its position in Cosmos Health stock. Citadel Advisors LLC increased its stake in Cosmos Health Inc. (NASDAQ:COSM) by 133.1% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 225,507 shares of the company’s stock after purchasing an additional 128,776 shares during the period. Citadel Advisors LLC owned approximately 0.65% of Cosmos Health worth $250,000 as of its most recent filing with the SEC. 12.61% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

COSM has been the subject of several research reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Cosmos Health in a report on Wednesday, October 8th. Wall Street Zen raised Cosmos Health to a “hold” rating in a report on Saturday, September 20th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company presently has a consensus rating of “Sell”.

About Cosmos Health

Cosmos Health Inc manufactures, develops, and trades branded nutraceutical products in Greece, the United Kingdom, Croatia, Bulgaria, Cayman Islands, and Cyprus. It offers medicines, OTC medicines, nutraceutical products, vitamins, minerals and dietary, health care products, medical devices, baby products, and others under the Sky Premium Life and Mediterranation brand names.